1. Rice Science
Leading Developer of Health, Wellness
and Performance Products from
Stabilized Rice Bran
1
Rice Science Confidential and Proprietary

2. Rice Science – The Company
 Rice Science was founded in January
2008
 Joint Venture
 Owned 80% NutraCea and 20% by
HerbalScience Group
 Company focused on the development
of functional ingredients from Stabilized
Rice Bran (SRB) Ric ie c
eSc ne
 Initial Targets - Inflammation and
Diabetes
 Develop functional ingredients through in
vitro/in vivo studies and human clinical
trials
 Other Targets
 Immune Enhancement
 Cardiovascular Enhancement
2
Rice Science Confidential and Proprietary

3. About NutraCea and HerbalScience
 NutraCea
 Leader in stabilized rice bran research and dietary supplement development
 Manufactures and distributes rice bran based products and ingredients
 Company has developed proprietary rice bran stabilizing technologies that
enable the creation of food and nutrition products from rice bran
 NutraCea develops families of health-promoting “nutraceutricals”
 HerbalScience Group
 Privately-held botanical technology company and a leading global producer of
evidence-based, dose-reliable functional ingredients with facilities in the
United States, Singapore and Shanghai
 Engaged in the discovery, development, manufacture and major brand JV-
marketing of proprietary botanical –based functional ingredients for health,
wellness and performance for the U.S. and international markets
 Wholly owned subsidiary HSRx is a pre-clinical platform technology company
that enables accelerated single molecule drug discovery from botanical and
other sources
3
Rice Science Confidential and Proprietary

4. Anti-Inflammatory and Diabetes Extracts
Key Steps in the Development of Optimized SRB Extracts
for Inflammation and Diabetes
Botanical Produce extracts Generate activity Comprehensive Mine data
with chemical data for extracts chemical/activity Identify key
diversity on multiple data set bioactive
targets for given 990
258
445
3345
6
766
55
6
998
45 2789
4
345
23
2 2223 234
65 567
2 23 2789
90 443
3
23 766 998 990 3345
2 2223 9 33 258 6
55
65 567 975 990 445 766 998 345
6
45 2789
4
23
2 2223 234
65 567
2 23 2789
90 443
3 2 2223 9
compounds
23 766 998
65 567 975 990
33
health end-point
Relative Abundance
3 9 33 1001 565 3 456 64 565 3 23 2789 3 9 33 1001 565 3 456 64 565 3 23 2789
5 975 990 88 6 6 2789 23 766 998 3 2 5 975 990 88 6 6 2789 23 766 998 3 2
2 23 2789 23 766 998 2 2223 9 33 443 65 2 23 2789 23 766 998 2 2223 9 33 443 65
234 3 2 2223 9 33 65 567 975 990 64 565 234 3 2 2223 9 33 65 567 975 990 64 565
90 443 65 567 975 990 565 3 23 2789 3 2 90 443 65 567 975 990 565 3 23 2789 3 2
456 64 565 3 23 2789 445 766 998 345 65 567 456 64 565 3 23 2789 445 766 998 345 65 567
2789 23 766 998 3 2 3 9 33 1001 565 3 2789 23 766 998 3 2 3 9 33 1001 565 3
2 2223 9 33 443 65 5 975 990 88 6 6 2 2223 9 33 443 65 5 975 990 88 6 6
Response
Relative Abundance
65 567 975 990 64 565 2 23 2789 23 766 998 65 567 975 990 64 565 2 23 2789 23 766 998
565 3 23 2789 3 2 234 3 2 2223 9 33 565 3 23 2789 3 2 234 3 2 2223 9 33
3 9 33 1001 565 3 90 443 65 567 975 990 3 9 33 1001 565 3 90 443 65 567 975 990
5 975 990 88 6 6 258 6 6 4 2 2223 5 975 990 88 6 6 258 6 6 4 2 2223
2 23 2789 23 766 998 445 766 998 345 65 567 2 23 2789 23 766 998 445 766 998 345 65 567
234 3 2 2223 9 33 3 9 33 1001 565 3 234 3 2 2223 9 33 3 9 33 1001 565 3
90 443 65 567 975 990 5 975 990 88 6 6 90 443 65 567 975 990 5 975 990 88 6 6
258 6 6 4 2 2223 2 23 2789 23 766 998 258 6 6 4 2 2223 2 23 2789 23 766 998
445 766 998 345 65 567 234 3 2 2223 9 33 445 766 998 345 65 567 234 3 2 2223 9 33
3 9 33 1001 565 3 90 443 65 567 975 990 3 9 33 1001 565 3 90 443 65 567 975 990
5 975 990 88 6 6 456 64 565 3 23 2789 5 975 990 88 6 6 456 64 565 3 23 2789
2 23 2789 23 766 998 2789 23 766 998 3 2 2 23 2789 23 766 998 2789 23 766 998 3 2
234 3 2 2223 9 33 2 2223 9 33 443 65 234 3 2 2223 9 33 2 2223 9 33 443 65
90 443 65 567 975 990 65 567 975 990 64 565 90 443 65 567 975 990 65 567 975 990 64 565
456 64 565 3 23 2789 565 3 23 2789 3 2 456 64 565 3 23 2789 565 3 23 2789 3 2
2789 23 766 998 3 2 90 443 65 567 975 990 2789 23 766 998 3 2 90 443 65 567 975 990
990 3345 55 45 2789 23 2 23 2789 23 766 998 990 3345 55 45 2789 23 2 23 2789 23 766 998
258 6 6 4 2 2223 234 3 2 2223 9 33 258 6 6 4 2 2223 234 3 2 2223 9 33
445 766 998 345 65 567 90 443 65 567 975 990 445 766 998 345 65 567 90 443 65 567 975 990
3 9 33 1001 565 3 456 64 565 3 23 2789 3 9 33 1001 565 3 456 64 565 3 23 2789
5 975 990 88 6 6 2789 23 766 998 3 2 5 975 990 88 6 6 2789 23 766 998 3 2
Dose 2
234
90
456
23
3
443
64
2789
2
65
565
23 766 998
2223 9 33
567 975 990 565
3
2 2223
3
9 33 443
23 2789 3
23 2789 445 766 998 345 65 567 456
65
65 567 975 990 64 565 234
2
2 23 2789
90 443
3
23 766 998
2 2223 9 33
65 567 975 990 565
64 565 3
2 2223 9 33 443
65 567 975 990 64 565
3 23 2789
23 2789 445 766 998 345 65 567
3
65
2
2789 23 766 998 3 2 3 9 33 1001 565 3 2789 23 766 998 3 2 3 9 33 1001 565 3
2 2223 9 33 443 65 5 975 990 88 6 6 2 2223 9 33 443 65 5 975 990 88 6 6
65 567 975 990 64 565 2 23 2789 23 766 998 65 567 975 990 64 565 2 23 2789 23 766 998
565 3 23 2789 3 2 234 3 2 2223 9 33 565 3 23 2789 3 2 234 3 2 2223 9 33
Individual Masses
3 9 33 1001 565 3 90 443 65 567 975 990 3 9 33 1001 565 3 90 443 65 567 975 990
Stabilized
5 975 990 88 6 6 258 6 6 4 2 2223 5 975 990 88 6 6 258 6 6 4 2 2223
COX1 2
234
23
3
2789
2
23 766 998 445 766 998 345 65 567
2223 9 33 3 9 33 1001 565 3 234
2 23 2789
3
23 766 998 445 766 998 345 65 567
2 2223 9 33 3 9 33 1001 565 3
5-LOX 90
258
445
443
6
766
65
6
998
567 975 990
4
345
2 2223
65 567 234
5 975 990
2 23 2789
3
88 6 6
23 766 998 258
2 2223 9
90 443
6
65 567 975 990
6
33 445 766 998 345
4 2 2223
65 567 234
5 975 990
2 23 2789
3
88 6
23 766 998
2 2223 9
6
33
Rice
3 9 33 1001 565 3 90 443 65 567 975 990 3 9 33 1001 565 3 90 443 65 567 975 990
5 975 990 88 6 6 456 64 565 3 23 2789 5 975 990 88 6 6 456 64 565 3 23 2789
2 23 2789 23 766 998 2789 23 766 998 3 2 2 23 2789 23 766 998 2789 23 766 998 3
Individual Masses
2
DART TOF-MS
234 3 2 2223 9 33 2 2223 9 33 443 65 234 3 2 2223 9 33 2 2223 9 33 443 65
90 443 65 567 975 990 65 567 975 990 64 565 90 443 65 567 975 990 65 567 975 990 64 565
COX2  AMPK 456 64 565 3 23 2789 565 3 23 2789 3 2 456 64 565 3 23 2789 565 3 23 2789 3 2
Bran PPAR FABP4 2789 23 766 998 3 2 90 443 65 567 975 990 2789 23 766 998 3 2 90 443 65 567 975 990
Rice Science Confidential and Proprietary 4

5. Rice Bran – A Rich Source of Bioactives
 SRB is among the most nutrient dense food ingredient with a rich diversity
of bioactive compounds
 More than 100 antioxidants & metabolic co-factors
 Vitamin E complex with complete tocotrienol profile
 Naturally rich in B Vitamins
 High in IP6 and Inositol
 Rich in γ-oryzanol and phytosterols
 Rich in essential fatty acids
 Complete and balanced Amino acid profile
 Contains compounds known to be beneficial in down-regulating pro-
inflammatory intermediates (i.e., γ-oryzanols) and maintaining blood
glucose moderation
 Rice Science Objective: Develop dosed assured, all natural extracts to
reduce inflammation and for moderation of blood glucose levels
5
Rice Science Confidential and Proprietary

6. Matrix of Extracts from SRB
Dose response curves are
Matrix of 14 generated for each extract
different extracts against each of several
produced from targets
SRB feedstock (COX1; COX2; 5-LOX,
FABP4, glucose uptake)
based on varying
extraction
conditions
Each SRB extract
is chemically
fingerprinted IC50 Curves
using
DART TOF-MS
6
Rice Science Confidential and Proprietary

7. SRB EXTRACT FOR INFLAMMATION
AND ARTHRITIS RELIEF
7

8. arthritis Market Place
 The rate of increase of osteoarthritis and rheumatoid
arthritis over the next two decades will almost double due
to the aging of the world’s population
 Arthritis is the most common cause of disability in the U.S.
 An estimated 28 million people in the US have arthritis or other
rheumatic conditions
 Arthritis represents a multi-billion (> $10 Billion) dollar
market globally
 Rx > $9B in 2007 (Primarily NSAID products)
 OTC $0.5B in 2007 (Primarily NSAID products)
 Supplements > $1.5B in 2007 (Primarily Glucosamine/Chondroitin)
8
Rice Science Confidential and Proprietary

9. Osteoarthritis
Healthy joint
 An estimated 27 million adults in the
United States live with osteoarthritis—
the most common type of arthritis
 Characterized by pain, inflammation,
joint damage, and limited motion
 Joint damage is not generally reversible Arthritic joint
 Management of pain and inflammation
can restore significant joint mobility and
function
 Highest success for relief of symptoms is
through control of pro-inflammatory
response Images by the National Institute of Arthritis and
Musculoskeletal and Skin Diseases
9
Rice Science Confidential and Proprietary

10. Rheumatoid Arthritis
 An estimated 1.3 million Americans suffer
from rheumatoid arthritis
 Chronic, systemic autoimmune disease
characterized by inflammation of the
synovium in the joints, bone loss, chronic
pain, loss of function and disability
 No cure
 Like osteoarthritis, preferred means of
controlling rheumatoid arthritis
symptoms is through the use of
analgesics (painkillers) and anti-
inflammatory drugs
http://www.niams.nih.gov/hi/
topics/arthritis/rahandout.htm 10
Rice Science Confidential and Proprietary

11. Pro-Inflammatory Pathways
 The major inflammatory pathways in
arthritis and related inflammatory Arachidonic Acid
disorders are regulated by Cyclo-
oxygenases (COX-1 and COX-2) and
Lipooxygenases (5-LOX) 5- LOX
 Most current drugs target COX-2 (e.g., COX-2 COX-1
Celebrex®) or are non-specific for COX-1
and COX-2 (e.g., aspirin and ibuprofen)
 NSAIDs associated with various side- Prostaglandins Leukotrienes
effects (e.g. ulcers)
 5-LOX has been recognized recently as a
key target as well
Pro-inflammatory cytokines
 Major effort underway by Pharma to and chemokines
develop Dual COX-LOX Inhibitors for
optimal efficacy
11
Rice Science Confidential and Proprietary

12. Glucosamine/Chondroitin Supplements
 Glucosamine/Chondroitin dominate supplements market for
arthritis products
 $831M in sales in 2007
 Glucosamine and chondroitin are not COX or LOX inhibitors
 NIH sponsored human clinical (GAIT) concluded that:
 The results showed that combination of glucosamine plus chondroitin sulfate
did not provide significant relief from osteoarthritis pain among all
participants
 The ancillary study results showed that glucosamine and chondroitin sulfate,
together or alone, appeared to fare no better than placebo in slowing loss of
cartilage in knee osteoarthritis
 Market is poised for alternative supplement that is effective
in providing relief from the symptoms of arthritis – All-natural
botanical extracts with dual COX-LOX inhibitory activities
12
Rice Science Confidential and Proprietary

13. Extracts with COX & LOX activities
 Two extracts identified with
very high COX-2 inhibitory
SRB-AI SRB-AII SR
activities and moderate COX- Enzyme
IC50 (μg mL-1) IC50 (μg mL-1) IC50
1 inhibitory activities
 One of the extracts (SRB-AII) COX1 305 310
also demonstrated moderate
5-LOX inhibitory activity COX2 29 19
 SRB-AI extract had no 5-LOX ND 396
measurable 5-LOX inhibitory
activity
An SRB-AI and SRB-II proprietary blend (SRB-AIII) was produced
to optimize the Dual COX-LOX inhibitory activities
13
Rice Science Confidential and Proprietary

14. Optimized SRB-AIII Extract
 Stabilized Rice Bran extract (SRB-
AIII) from Rice Science possesses Arachidonic Acid
COX-1, COX-2 and 5-LOX 5-LOX
inhibitory activities
SRB Extract
 COX-1 IC50 value = 48 μg mL-1
COX-1 COX-2
 COX-2 IC50 value = 11 μg mL-1
 5-LOX IC50 value = 197 μg mL-1 Prostaglandins
Leukotrienes
 First-in-class all-natural extract
with dual COX-2/5-LOX inhibitory INFLAMMATORY RESPONSE
activities
14
Rice Science Confidential and Proprietary

15. Identification of Bioactives
Importance of Identifying Anti-Inflammatory Bioactives
 Intellectual Property
 Composition-of-Matter
 Methods-of-Making
 Methods-of-Use
 Ingredient Production
 Verify presence of bioactives in feedstock
 Optimize extraction to enrich for bioactives
 Guarantee presence of bioactives in all batches at doses that deliver
efficacy
 Provides a “dose assured” functional ingredient
 Ingredients that work
15
Rice Science Confidential and Proprietary

16. Bioactive Chemistries in SRB-AIII
In addition to 17 bioactives with “known” structure, 4 novel bioactives with
previously unknown structures have been identified in SRB-AIII that have
significant COX-1/COX-2 and 5-LOX inhibitory activities
Molecular Molecular Chemical Relative Wt per 100 mg Theoretical IC50 Theoretical IC50 Theoretical IC50
Compound Name
Formula Mass (M) Class Abundance (%) (mg) (mM) (COX1) (mM) (COX2) (mM) (5-LOX)
norcamphor/heptadienal C7H10O + H+ 110.08 terpene 0.45 452 197 45 809
+
6-methyl-5-hepten-2-one C8H14O + H 126.11 terpene 3.24 3,237 1232 282 5057
ocimene/camphene/adamantane C10H16 + H+ 136.12 terpene 1.42 1,418 500 115 2052
histidinol C6H11N3O + H+ 142.11 imidazole 2.86 2,863 967 222 3969
lysine C6H14N2O2 + H+ 146.12 amino acid 0.42 421 138 32 568
tryptamine C10H12N2 + H+ 160.12 amino acid 0.39 388 116 27 477
+
Nonanedioic acid anhydride C9H14O3 + H 170.11 fatty acid 1.81 1,815 512 117 2102
Nonanedioic acid diamide C9H18N2O2 + H+ 187.14 fatty acid 1.92 1,920 492 113 2021
Epiloliolide C11H16O3 + H+ 196.12 alkaloid 5.74 5,745 1406 322 5771
Farnesatrienetriol C15H26O3 + H+ 254.36 terpene 5.08 5,076 958 220 3931
Farnesylacetone C18H30O + H+ 262.43 terpene 27.13 27,131 4962 1137 20367
Octadecatrienol C18H32O + H+ 264.45 fatty acid 16.61 16,614 3016 691 12376
octadecatrienoic acid C18H30O2 + H+ 278.43 fatty acid 100.00 100,000 17240 3951 70754
hydroxyoctadecatrienoic acid C18H30O3 + H+ 294.43 fatty acid 28.57 28,571 4658 1067 19117
hydroxyoctadecenoic acid C18H34O3 + H+ 298.46 fatty acid 15.37 15,374 2473 567 10148
epoxyhydroxyoctadecanoic acid C18H32O4 + H+ 312.27 fatty acid 12.67 12,671 1948 446 7994
12-shoagol C23H36O3 + H+ 360.28 gingerol 4.35 4,348 579 133 2377
16
Rice Science Confidential and Proprietary

17. Pharmacokinetics of SRB-AIII
1.20
 Vegetable capsules with 1.00 Uptake of 3 SRB-AIII #1
SRB-AIII extract given to 0.80
RiceRx
bioactives into human serum
RiceRx #2
RiceRx #3
5 human subjects
Normalized Intensity
0.60
 Uptake of key bioactives 0.40
into serum and 0.20
appearance in urine was
monitored using DART
0.00
0 50 100 150 200 250 300 350 400 450 500
Time (minutes)
TOF-MS 0.12
Appearance of 3
Uptake of key bioactives
0.10
 RiceRx #1
bioactives into urine
RiceRx #2
RiceRx #3
occurred within 40
0.08
Normalized Intensity
minutes of oral dose
0.06
0.04
 Key bioactives appeared 0.02
in urine within first hour 0.00
0 1 2 3 4 5 6 7 8 9
Time (hours)
17
Rice Science Confidential and Proprietary

18. Structure-Function Claims*
 Enriched in bioactives that inhibit the activity of pro-
inflammatory enzymes COX-1-, COX-2 and 5-LOX in vitro
 Dual-function extract that targets the two major pathways
controlling inflammation and pain associated with arthritis
and related inflammatory diseases
 Synergistic bioactives that promote healthy joints
 Key bioactives taken up rapidly, within 40 minutes
* These statements have not been evaluated by the Food and Drug Administration. This
product is not intended to diagnose, treat, cure, or prevent any diseases
18
Rice Science Confidential and Proprietary

19. Human Clinical trial
 Rice Science plans to sponsor a human clinical trial
(2010) to examine efficacy of SRB-AIII in relieving
symptoms of arthritis
 Primary outcome will measure onset of pain relief in
arthritic knee during course of exercise and measure
levels of cytokine pro-inflammatory markers following
oral dosing with SRB-AIII in a randomized double-blind
placebo controlled study
 Secondary outcome will monitor joint health and
function in a 30-day open label study in which subjects
will self-monitor joint function in 6 minute walks and
filling out of questionnaires. Pro-inflammatory cytokine
markers will also be monitored at end of 30 days
19
Rice Science Confidential and Proprietary

20. SRB EXTRACT FOR DIABETES
20

21. Diabetes Market Place
 Type 2 diabetes related to age and obesity, characterized by
insulin resistance which elevates blood sugar
 Over 23 million Americans suffer from type 2 diabetes
 Of these, over 16 million are diagnosed
 The American Diabetes Association estimates that 1 in 3
Americans will be diagnosed with diabetes in their lifetime
 Medical expenses related to diabetes exceed $ 132B in the
U.S. annually
 Diabetes is a subset of what is called Metabolic Syndrome
which includes cardiovascular disease and obesity

22. Type 2 Diabetes
 Symptoms include:
 Abnormally high blood sugar
 Fatigue and lack of energy
 Frequent urination
 Unexplained weight loss
 Blurred vision that can lead to blindness
 Slow healing of wounds
 Cardiovascular disease

23. Metabolic Syndrome
 Metabolic Syndrome is a
combination of disorders
that increase the risk of
developing cardiovascular
disease and diabetes
 Diabetes is a major disorder
of Metabolic Syndrome
 The SRB extract developed
by Rice Science addresses
two key processes in
Metabolic Syndrome,
glucose and fat utilization

24. SRB Extract for Diabetes
A number of SRB extracts were tested for diabetes
endpoints with one indentified as most effective and
designated SRB-D1

25. Effect of SRB-D1on
Glucose Uptake
 SRB-D1 stimulated glucose
uptake in adipocytes more
effectively than insulin

26. Effect of SRB-D1 on
FABP4 Protein
 SRB-D1 has a moderating
effect on FABP4 protein
which plays a role in type 2
diabetes, atherosclerosis
and obesity

27. Pharmacokinetics of SRB-D1
 Vegetable capsules with
SRB-D1 extract given to 5
subjects
 Uptake of key bioactives
into serum was monitored
using DART TOF-MS
 Uptake of key bioactives
occurred within 20 – 45
minutes

28. Rice Science
VALUE PROPOSITION
28
Rice Science Confidential and Proprietary

29. Value Proposition
 All-natural first-in-class dose-reliable botanical extract with dual
COX-LOX inhibitory activities for inflammation and arthritis
 All-natural, dose reliable extract for moderating glucose serum
levels in diabetics
 Strong structure-function claims backed by solid in vitro and
human clinical studies
 Significant product differentiation
 Dose assured functional SRB extracts manufactured through
proprietary methods that ensure the presence and functional
levels of key bioactives in every batch
 Comprehensive and strong IP and patent position
• Composition-of-matter, methods-of-making, and methods-of use (mode-of-
action)
Rice Science Confidential and Proprietary 29

30. Contact Information
NutraCea NutraCea
Leo Gingras Colin Garner
President and Chief Operating
Sr. Vice President
Officer
lgingras@nutracea.com CGarner@NutraCea.com
6720 N. Scottsdale Road, Suite 390 6720 N. Scottsdale Road, Suite 390
Scottsdale, AZ 85253 Scottsdale, AZ 85253
Office: 602-522-3011 Cell: 602-909-0327
Fax: 602-522-7575 Office: 877-723-1700